Secondly, MGMT promoter methylation status was a significant prognostic factor; however, its data were absent because most of the patients are not tested in our study, leading to the role of MGMT promoter status in our inability to assess short-term glioma recurrence. The gene discussed is MGMT; the disease is central nervous system cancer.